Keyphrases
Chronic Kidney Disease
100%
HIV Infection
100%
Risk Score
100%
D Study
100%
Donor-acceptor
100%
Cohort Data
100%
Estimated Glomerular Filtration Rate
26%
Atazanavir
26%
HIV-positive
20%
Media Risk
20%
Number Needed to Harm
20%
High Risk
13%
Low Risk
13%
Antiretroviral
13%
Group Risk
13%
Risk Score Model
13%
Lopinavir
13%
Boosted Protease Inhibitors
13%
Tenofovir
13%
Clinical Significance
6%
Adverse Events
6%
Cardiovascular Disease
6%
Control Arm
6%
Old Age
6%
Treatment Regimen
6%
Female Gender
6%
External Validation
6%
Poisson Regression
6%
Clinical Practice
6%
Incidence Rate
6%
Proteinuria
6%
High-risk Population
6%
CD4 Count
6%
Health Problems
6%
Diabetes Disease
6%
Categorical Variables
6%
Hypertension Disease
6%
HIV-related
6%
Related Risk Factors
6%
Long-run Risk
6%
Event Risk
6%
Royal
6%
Hepatitis C Coinfection
6%
Low-risk Group
6%
ESPRIT
6%
Intravenous Drug Use
6%
Unboosted
6%
Anti-HIV Drugs
6%
Hospital Clinic
6%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
Human Immunodeficiency Virus Infection
100%
Glomerulus Filtration
80%
Tenofovir
40%
Hepatitis C
20%
CD4 Lymphocyte Count
20%
Arm
20%
High Risk Population
20%
Coinfection
20%
Decision Making
20%
Low Risk Population
20%
Nursing and Health Professions
Chronic Kidney Failure
100%
Human Immunodeficiency Virus Infection
100%
Human Immunodeficiency Virus
33%
Estimated Glomerular Filtration Rate
26%
Atazanavir Plus Ritonavir
20%
Number Needed to Harm
20%
Lopinavir Plus Ritonavir
20%
Proteinase Inhibitor
13%
Tenofovir
13%
Hepatitis C
6%
Hospital
6%
Cardiovascular Disease
6%
Clinician
6%
Adverse Event
6%
Clinical Practice
6%
High Risk Population
6%
Rate Ratio
6%
Drug Use
6%
CD4 Lymphocyte Count
6%
Mixed Infection
6%
Atazanavir
6%
Low Risk Population
6%
Proteinuria
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Human Immunodeficiency Virus Infection
100%
HIV
26%
Number Needed to Harm
20%
Lopinavir Plus Ritonavir
20%
Atazanavir Plus Ritonavir
20%
Proteinase Inhibitor
13%
Tenofovir
13%
Adverse Event
6%
Cardiovascular Disease
6%
Hepatitis C
6%
Mixed Infection
6%
Atazanavir
6%
Proteinuria
6%
Anti-Human Immunodeficiency Virus
6%
Mathematics
Median
100%
Categorical Variable
33%
Rate Value
33%
Poisson Regression
33%
Incidence Rate
33%
Interquartile Range
33%